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Summary
 
Interleukin (IL)-12 is expressed mainly in antigen-presenting cells after challenge with micro-
bial material or after CD40 activation. Although IL-12 was cloned from human Epstein-Barr
virus (EBV)-transformed B cell lines, surprisingly, CD40 ligation on murine B cells did not
lead to IL-12 production, suggesting that murine B cells do not produce IL-12. Here we dem-
onstrate that a subset of human tonsillar B cells can be induced to express and secrete bioactive
IL-12. The major stimulus to produce IL-12 in human B cells was CD40 ligation. In contrast,
B cell receptor cross-linking did not induce IL-12. Expression of IL-12 after CD40 activation
 
was restricted to CD38
 
2
 
IgD
 
6
 
 non-germinal center (non-GC) B cells. CD40 ligation and inter-
 
feron (IFN)-
 
g
 
 exhibited synergistic effects on IL-12 production, whereas IL-10 abrogated and
IL-4 significantly inhibited IL-12 production by these B cells. In contrast to IL-12, production
of IL-6 is conversely regulated, leading to significant increase after CD40 ligation in the pres-
ence of the T helper type 2 (Th2) cytokine IL-4. Cord blood T cells skewed towards either a
Th1 or a Th2 phenotype maintained their cytokine expression pattern when restimulated with
allogeneic resting B cells. Blockade of CD40 and/or IL-12 during T–B interaction significantly
reduced IFN-
 
g
 
 production by the T cells. This suggests a model whereby B cells produce ei-
ther IL-12 or IL-6 after contact with T cells previously differentiated towards Th1 or Th2.
Furthermore, IL-12 and IL-6 might provide a positive feedback during cognate T–B interac-
tions, thereby maintaining T cells’ differentiation pattern during amplification of the immune
response.
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T
 
he current model of T cell–mediated immune re-
sponse suggests that priming and activation of T cells
occur in secondary lymphoid organs (1). First, professional
 
APCs, especially dendritic cells (DCs),
 
1
 
 present antigen to
naive T cells in the T cell zone (2, 3). This initial priming
step involves cell-to-cell contact between APCs and T cells
that engages MHC molecules on the APC and TCR mole-
cules on the T cell. Sufficient expression of adhesion and
costimulatory molecules on the APCs assures efficient T
cell activation (4–7), and the expression of cytokines by
APCs, such as IL-12 and IL-6, can lead to T cell polariza-
tion (for reviews, see references 2–6). It is now widely ac-
cepted that the major sources of IL-12 are DCs (7–10) and
activated macrophages (11, 12). IL-12 production is in-
duced either directly by microbacterial compounds in a T
cell–independent mechanism (13, 14) or by a T cell–
dependent route that uses CD40L–CD40 interactions be-
tween T cells and APCs (8–10). Although CD40 ligation
on B cells is a major signal for activation, differentiation,
isotype class switching (15), and upregulation of cytokines
and cell surface molecules (16), it remains unclear whether
normal human B cells express IL-12 after CD40 activation
(17). It has been reported that IL-6 expressed by APCs can
induce T cells to produce IL-4 (18), and this cytokine
might therefore be a factor responsible for inducing Th2
responses. IL-6 is expressed by a variety of cells including B
cells, but monocytic cells are the major source (19).
 
1
 
Abbreviations used in this paper:
 
 DC, dendritic cell; GC, germinal center;
MBD, magnetic bead depletion; MIF, mean intensity of fluorescence; rh,
recombinant human; sIg, surface immunoglobulin; t-CD40L; CD40
ligand transfectants; t-mock, control transfectants. 
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IL-12 Production by Human B Cells
 
Although there is no doubt regarding the key role of
DCs in processing and presentation of antigen and initia-
tion of a T cell immune response, questions remain about
their role later during the immune response. Since in vivo
data have demonstrated that antigen-bearing DCs disappear
from secondary lymphoid organs after 24–48 h of initial
antigen inoculation (13, 20), mechanisms of maintaining,
amplifying, and diversifying this initial T cell activation
have to exist to explain the subsequent expansion of the
immune response after initiation (21). One explanation
could be that this short period of antigen presentation by
DCs is sufficient to induce not only T cell activation, but
also expansion. In vivo data in murine model systems using
tumor-specific peptide-pulsed DCs support this notion
(22–28). However, when antigen-specific T cells in vivo
are followed over time during an immune response, it has
been clearly demonstrated that they migrate to the outer T
cell zone (21) and then to the B cell area (29) where cog-
nate T–B interactions between antigen-specific T and B
cells occur, leading to further expansion of both T and B
cells. This intermediate step is followed by the develop-
ment of a germinal center (GC) reaction, leading to further
expansion of antigen-specific B cells but also T cells inside
the GC (21).
T cell polarization of naive T cells towards Th1 or Th2
subsets can occur in 48 h after activation (30, 31) and pre-
sumably occurs during interaction with DCs in the T cell
zone. However, if polyclonal T cell populations are polar-
ized towards Th1 or Th2 subtypes, they can be converted
to the opposite phenotype when exposed thereafter to IL-4
or IL-12, respectively (32, 33). It remains unclear if and
how T cell polarization is determined during the latter
phases of the immune response, when T cells are migrating
to the outer T cell zone and subsequently to the GC to
meet antigen-specific B cells. It could be possible that T
cells are resistant to any further skewing by the microenvi-
ronment once they have completed their polarization pro-
gram. Alternatively, T cell polarization could be further
stabilized by the microenvironment during migration, most
likely during cognate T–B cell interactions, supporting not
only B cell (34) but also T cell differentiation. Our work-
ing hypothesis is that a positive feedback loop between the
antigen-presenting B cell and the T cell exists during cog-
nate T–B interactions in the outer T cell zone, and that this
mechanism is mediated by cytokines, including IL-6 and
IL-12, analogous to that expressed by APCs. We would
further hypothesize that the expression of these cytokines
by B cells is precisely regulated by signals delivered by the
activated T cells and not by signals mediated via the B cell
receptor or through MHC signals. To test this hypothesis,
we analyzed human tonsillar B cells for their expression of
IL-12 and IL-6 and the signals that induce these cytokines.
Although IL-12 was cloned from human EBV-transformed
B cell lines (35–38), protein expression in normal human
tonsillar B cells has not yet been described (17). We show
here that IL-12 is induced in a small fraction of IgD
 
1
 
 and
IgD
 
2
 
 non-GC B cells after CD40 activation, increased by
the Th1 cytokine IFN-
 
g
 
 and negatively regulated by IL-4
 
and, more significant, by IL-10. We detected IL-6 produc-
tion by non-GC B cells (39) that was mainly induced after
CD40 activation and IL-4 (40). In keeping with the model
of Mamula and Janeway (1), we suggest that B cells are sec-
ond line APCs able to support an ongoing T cell response
initiated by DCs.
 
Materials and Methods
 
Donors.
 
Human PBMCs from healthy donors were obtained
by phlebotomy or leukopheresis. Cord blood was obtained after
delivery. Tonsils were obtained as discarded tissue after routine
tonsillectomy. All specimens were obtained after approval by the
Institutional Review Board. Informed consent for blood dona-
tions was obtained from all volunteers.
 
B Cells.
 
Tonsillar B cells were obtained from human tonsils.
Cells were mechanically homogenized in medium containing
magnesium and calcium and mashed through a 40-
 
m
 
m sieve to
clear the cell solution from tissue fragments and cell clusters
known to contain the vast majority of DCs (41). The single cell
suspension obtained was subsequently ficoll density centrifuged
and rosetted over sheep erythrocytes (42) followed by magnetic
bead depletion (MBD) of CD4
 
1
 
, CD8
 
1
 
, CD14
 
1
 
, and CD56
 
1
 
cells (16, 43–45). As determined by FACS
 
®
 
 analysis, B cell purity
always exceeded 97%, with few CD3
 
1
 
 cells. Of particular impor-
tance, no CD19
 
2
 
CD3
 
2
 
 cells were found that stained with
CD11a, CD14, CD33, CD83, or MHC class II. GC B cells were
isolated by MBD using an anti-CD44 mAb (a gift of Dr. S. Can-
nistra, Dana-Farber Cancer Institute). This resulted in a cell pop-
ulation uniformly expressing CD19, CD20, and CD38, resem-
bling the immunophenotype of GC B cells. For purification of
resting non-GC B cells containing both naive IgD
 
1
 
 and memory
IgD
 
2
 
 CD38
 
2
 
 B cells, a CD38 mAb (Coulter Corp.) was added
during MBD, resulting in a population of cells 
 
.
 
98% of which
were CD38
 
2
 
CD19
 
1
 
CD20
 
1
 
 B cells.
 
T Cells.
 
Adult CD3
 
1
 
CD4
 
1
 
 T cells were obtained from PB-
MCs. Removal of adherent cells by plastic adherence was fol-
lowed by MBD of non-T cells (16, 43, 44) using mAbs against
CD11a (Mo1), CD14 (Mo2), CD19 (B4), CD8 (T8), and CD56
(3G8). Preparations were always 
 
.
 
97% CD3
 
1
 
CD4
 
1
 
 as assessed
by immunophenotypic analysis. Where indicated, T cells were
further enriched for CD45RA
 
1
 
 T cells using a CD45RA
 
1
 
 mAb
(UCHL1; gift of Dr. C. Morrimoto, Dana-Farber Cancer Insti-
tute) during MBD. Cells were always 
 
.
 
75% CD45RA
 
1
 
 as deter-
mined by FACS
 
®
 
 analysis. Cord blood T cells were purified by
rosetting over sheep red blood cells followed by MBD as de-
scribed above, and were always 
 
.
 
97% CD3
 
1
 
CD45RA
 
1
 
CD4
 
1
 
.
 
CD40L and Mock Transfectants.
 
As described previously (16,
43, 44), murine NIH3T3 fibroblasts transfected with the human
CD40L (t-CD40L cells) or vector alone (t-mock) were used for
stimulation of human B cells. Phenotypic analyses were per-
formed regularly on these cells and in all analyses 
 
.
 
95% of
t-CD40L cells were positive for human CD40L with a mean in-
tensity of fluorescence (MIF) between 80- and 300-fold over
background (MIF
 
 5 
 
10), whereas t-mock cells were always
found to be negative. Transfectants were grown in medium con-
taining 45% DMEM (GIBCO BRL), 45% F12 (GIBCO BRL),
10% FCS, 2 mM glutamine (GIBCO BRL), and 15 
 
m
 
g/ml
gentamicin (GIBCO BRL). For B cell cultures, t-CD40L and
t-mock cells were lethally irradiated (96 Gy) and subsequently
plated on 6- or 24-well plates (Costar Corp.) at a concentration
of 0.4 
 
3 
 
10
 
5
 
 cells/well. After an overnight culture at 37
 
8
 
C in 5% 
3
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CO
 
2
 
, t-CD40L cells were adherent and could be used for cocul-
ture.
 
B Cell Cultures.
 
B cells were stimulated with various stimuli
for up to 96 h in medium based on Iscove’s MDM (GIBCO
BRL) supplemented with 2% FCS, 50 
 
m
 
g/ml human transferrin
(Boehringer Mannheim), 5 
 
m
 
g/ml human insulin (Sigma Chemi-
cal Co.), and 15 
 
m
 
g/ml gentamicin at 37
 
8
 
C in 5% CO
 
2
 
. B cells
were stimulated at a concentration of 1 or 2 
 
3 
 
10
 
6
 
 cells/ml with
mAbs against the cell surface Ig (goat anti–human IgG and IgM
Fc F(ab
 
9
 
)
 
2
 
 fragments, 10 
 
m
 
g/ml; Jackson ImmunoResearch Labo-
ratories [46]), anti–MHC class II mAbs (9-49, 10 
 
m
 
g/ml [43,
44]), or the cytokines IL-2 (50 IU/ml; gift of Dr. J. Ritz, Dana-
Farber Cancer Institute), IL-4 (10 ng/ml; Immunex), IL-6 (5 ng/
ml; Genzyme), IL-10 (10 ng/ml; Genzyme), and IFN-
 
g 
 
(20 ng/
ml; Genzyme), or combinations of these cytokines. For stimula-
tion via CD40, cells were cocultured with adherent irradiated
t-CD40L cells and with t-mock cells for control experiments.
 
DCs and Monocytes.
 
For control experiments, monocytes
were isolated from peripheral blood by ficoll density centrifuga-
tion and rosetting over sheep erythrocytes. Nonrosetting cells
were mostly CD14
 
1
 
 with few CD83
 
1
 
 DCs or CD19
 
1
 
 B cells.
These cells were stimulated with IFN-
 
g
 
 (20 ng/ml) for 2 h fol-
lowed by LPS (10 ng/ml) and IFN-
 
g
 
 (20 ng/ml) for 22 h before
analysis for intracellular IL-12. For these experiments, Brefeldin
A (Sigma Chemical Co.) was added at 10 
 
m
 
g/ml for the last 22 h.
DCs were generated from monocyte-enriched fractions by cul-
ture with GM-CSF (50 ng/ml; Immunex) and IL-4 (10 ng/ml;
Genzyme) for 5–8 d, followed by stimulation via CD40 using
t-CD40L cells for 24–72 h (16). Supernatants of these cultures
were harvested and stored at –80
 
8
 
C until use.
 
Immunofluorescence Studies.
 
Purity of cell populations under
study was determined by dual-color FACS
 
®
 
 analysis using di-
rectly conjugated mAbs for CD3 (CD3; Coulter Corp.), CD4
(T4; Coulter Corp.), CD8 (T8; Coulter Corp.), CD14 (Tük4,
anti–human IgG and IgM Fc fragment F; DAKO), CD83
(HB15; Coulter Corp.), CD19 (B4; Coulter Corp.), CD20 (B1;
Coulter Corp.), CD38 (HBV; Becton Dickinson), CD44
(DF1485; DAKO), CD56 (N901; Coulter Corp.), and surface
(s)IgD (DAKO).
 
Detection of p70 and p40 IL-12 in B Cell Culture Supernatants.
 
Supernatants from B cell cultures were harvested after 18–96 h of
culture and stored at –80
 
8
 
C until analysis. As positive controls,
supernatants from blood-derived DCs were also analyzed. Both
p70 IL-12 and p40 IL-12 were analyzed by sandwich ELISA us-
ing matched antibody pairs (R&D Systems). In brief, anti-p40
IL-12 (5 
 
m
 
g/ml) or p70 IL-12 (5 
 
m
 
g/ml) were plated overnight
at room temperature in PBS onto MaxiSorb
 
®
 
 plates (Nunc).
Plates were washed using 0.05% Tween 20 in PBS, pH 7.4, and
subsequently blocked using PBS containing 5% Tween 20, 5%
sucrose, and 0.05% NaN
 
3
 
. Plates were again washed four times
before standards (recombinant human [rh]IL-12 or rh p40 IL-12
in B-2) or supernatants from B cell cultures were incubated for
2 h at room temperature. Plates were again thoroughly washed
followed by a 2-h incubation using biotinylated anti–IL-12 mAbs
(350 ng/ml; R&D Systems). Plates were incubated subsequently
with streptavidin–horseradish peroxidase (1:5,000; Zymed Labo-
ratories, Inc.) for 1 h. TMB (DAKO) was used as substrate and
0.18 M H
 
2
 
SO
 
4
 
 to stop the enzymatic reaction after 30–60 min.
Plates were read using an automated ELISA reader and analyzed
with Soft MAX Pro
 
®
 
 software (Molecular Devices Corp.).
 
IFN-
 
g
 
 Production by CD3
 
1
 
CD4
 
1
 
 T Cells as Bioassay for IL-12
Detection.
 
Human purified CD3
 
1
 
CD4
 
1
 
 T cells were stimulated
with PMA (1 ng/ml; Sigma Chemical Co.) and CD28 mAbs
 
(clone 3D10, 2 
 
m
 
g/ml) at 10
 
5
 
 cells/ml in RPMI 1640 (Cellgro
Mediatech) supplemented with 10% human AB serum (Sigma
Chemical Co.), 2 mM glutamine (GIBCO BRL), 15 
 
m
 
g/ml gen-
tamicin (GIBCO BRL), hereafter referred to as RPMI-10, in
200 
 
m
 
l final vol/well in 96-well plates (Falcon; Becton Dickin-
son) in triplicate for 48 h at 37
 
8
 
C in a 5% CO
 
2
 
 atmosphere before
supernatants were harvested from the cultures. Exogenous rhIL-
12 (R&D Systems) was added to these cultures at concentrations
ranging from 1 to 1,000 pg/ml. To measure bioactive IL-12 from
culture supernatants of the B cell cultures, a 50% vol of B cell
culture supernatant was added to the T cell culture. Culture su-
pernatants from the T cell cultures were then analyzed for IFN-
 
g
 
by ELISA using matched pairs of anti–IFN-
 
g
 
 antibodies follow-
ing the provider’s instructions (Endogen). To confirm that IL-12
was indeed responsible for IFN-
 
g
 
 production by the T cells, a
neutralizing mAb for IL-12 (10 
 
m
 
g/ml; R&D Systems) was
added when indicated throughout the whole culture period. To
control for equivalent activation and proliferation in these cul-
tures, thymidine incorporation ([
 
3
 
H]Tdr, 1 mCi/well; DuPont-
NEN) was measured for the last 16 h of a 72-h culture after su-
pernatants had been removed.
 
Detection of p40/p70 IL-12 by Intracellular Staining.
 
Intracellu-
lar IL-12 in monocytes and B cells was detected by FACS
 
®
 
 anal-
ysis using a directly labeled anti–IL-12 mAb (C11.5; PharMin-
gen). B cells were stimulated with t-CD40L cells with or without
IFN-
 
g
 
 (20 ng/ml). After 14–16 h, Brefeldin A (10 
 
m
 
g/ml) was
added to the cultures and the cells were cultured for another 6–8 h.
Addition of Brefeldin A during earlier time points or for shorter
times at the end of the B cell cultures resulted in a decreased
detection of intracellular cytokines. Cells were harvested, washed
with PBS, and incubated with mouse Ig (60 
 
m
 
g/ml; Jackson
ImmunoResearch Laboratories) for 10 min to block unspecific
binding, followed by the addition of directly labeled mAbs to
CD19, CD20, or sIgD for 30 min to detect extracellular ex-
pression of these molecules. After washing with PBS, cells were
first paraformaldehyde fixed for 20 min using the Perm and FIX
kit from Caltag, followed by permeabilization and intracellular
staining for 30 min using either anti–IL-12 (C11.5; PharMingen)
or anti–IL-6 mAbs (M02-1305; PharMingen). Cells were finally
washed in PBS again and resuspended in PBS supplemented with
0.1% formaldehyde. All incubations were carried out at room
temperature. Cells were immediately analyzed using a Coulter
EPICS XL Elite flow cytometer. Data are displayed as dot plots
of PE (x-axis) and FITC (y-axis) fluorescence (four decade log
scales).
 
Cytokine Production Analysis in T–B Cultures.
 
Naive cord blood
T cells were stimulated primarily with CD3 plus CD28 mAbs
bound to tossyl beads in the presence of IL-2 and either IL-12
plus anti–IL-4 mAbs or IL-4 and anti–IFN-
 
g
 
 mAbs for 3–6 d.
Cells were washed extensively, rested for 6–8 h on ice, and re-
stimulated with allogeneic resting CD19
 
1
 
CD38
 
2
 
sIgD
 
6
 
 B cells
for 24–72 h before supernatants were analyzed for IFN-
 
g
 
 and IL-4
by ELISA. Where indicated, neutralizing anti–IL-12 mAb,
blocking anti-CD40L mAb (anti-CD40L mAb clone M90, 10
 
m
 
g/ml; Immunex), or both were added to the cultures. To test
whether CD40-activated B cells produce IL-12 and can induce
IFN-
 
g
 
 by T cells, adult CD3
 
1
 
CD4
 
1
 
 T cells (2 
 
3 
 
10
 
6
 
 T cells/ml)
from healthy individuals enriched for CD45RA
 
1
 
 (
 
.
 
75%) were
stimulated in an allogeneic MLR with irradiated (32 Gy) CD40-
activated CD19
 
1CD382sIgD6 tonsillar B cells (106 cells/ml). T
cells were stimulated for 5 d, then ficoll density centrifuged to re-
move nonviable cells before resting in medium for 24 h. Where
indicated, neutralizing anti–IL-12 mAb (10 mg/ml; R&D Sys-4 IL-12 Production by Human B Cells
tems) was added. T cells were then restimulated with the same al-
logeneic CD40-activated B cells for up to 6 d depending on the
assay performed thereafter. Supernatants from these cultures were
harvested at different times during culture and were analyzed for
IL-4, IL-6, IL-10, or IFN-g by ELISA (Endogen). T cell prolif-
eration during secondary stimulation was determined by [3H]thy-
midine incorporation in triplicate on days 2, 4, and 6. Following
the same procedure described above, intracellular IFN-g and IL-4
were analyzed in T–B cell cultures using anti–IFN-g (4S.B3;
PharMingen) and anti–IL-4 mAbs (MP4-25D2; PharMingen).
Results
CD40 Activation Is the Major Stimulus for Human Tonsillar
B Cells to Produce IL-12. Since human DCs have been
shown to produce IL-12 after CD40 activation (7–10), we
first attempted to determine whether CD40 activation
might also induce normal human B cells to produce IL-12.
Tonsillar B cells (.97% CD191) were isolated and cul-
tured (a) in medium, (b) with control transfectants (t-mock),
or (c) with CD40L transfectants (t-CD40L) for up to 96 h.
Supernatants were examined for p40 and p70 IL-12 by
ELISA. As shown in Fig. 1 A, unfractionated tonsillar B
cells were induced to produce both p40 and the biologi-
cally active heterodimer p70 IL-12 after CD40 activation,
whereas no IL-12 was detected in control cultures. Al-
though p40 IL-12 significantly increased over time, the
highest level of p70 IL-12 was detected after 24 h and de-
clined thereafter. The decrease of the p70 heterodimer dur-
ing later time points of the culture is most likely a result of
dissociation of the two chains due to decreasing pH in
these cultures. Control experiments demonstrated that sim-
ilar amounts of rhIL-12 dissolved in PBS lead to signifi-
cantly reduced detection of IL-12 with decreasing pH
(to 7.2–6) as assessed by ELISA analysis (data not shown).
As described for macrophages (47), the concentration of
p40 IL-12 was always 10–50-fold higher than that of p70
IL-12.
We next examined whether human tonsillar B cells
could be induced to produce IL-12 by various other stim-
uli, including B cell receptor cross-linking using mAbs, an-
tibodies against MHC class II molecules, Th1 cytokines
IL-2 and IFN-g, or Th2 cytokines IL-4, IL-6, and IL-10.
Again, p40 IL-12 and the p70 IL-12 heterodimer were
measured in B cell culture supernatants by ELISA after 24 h.
In six individual experiments, CD40L was identified to
be the most effective stimulus for IL-12 p40 production
(mean 6 SD in Fig. 1 B). Of all other stimuli tested, only
IFN-g, IL-2, and MHC class II cross-linking mAbs in-
duced p40 IL-12 threefold above detection level. Signifi-
cant amounts of p70 IL-12 were only detected in B cell
cultures stimulated with CD40L, IFN-g, or anti–MHC
class II mAb. In control experiments, we analyzed human
monocyte-derived DCs (generated by culture with GM-
CSF and IL-4 for 5–8 d and further differentiated by CD40
activation for 24–72 h [10]) for their production of IL-12
using the same ELISA method. These in vitro–generated
DCs produced higher amounts (two- to fivefold) of both
IL-12 p40 and p70 than unseparated tonsillar B cells, with a
different kinetics for p70 IL-12, with levels peaking at 48–
72 h after CD40 activation (data not shown). A potential
reason for lower IL-12 production by B cells could be that
the production of IL-12 is restricted to certain differentia-
tion periods and therefore only a small fraction of tonsillar
B cells might be responsible for IL-12 production.
Naive and Memory B Cells Produce IL-12. To determine
further whether production of IL-12 p40 and p70 was re-
stricted to B cell subsets, we purified GC B cells (CD191
CD381CD442) and non-GC B cells (CD191CD382
CD441) from human tonsillar B cells (Fig. 2 A) and stimu-
lated them with CD40L for 24–96 h. These experiments
clearly identified non-GC B cells as the source of IL-12
p40 and p70 (Fig. 2 B). To further confirm that non-GC B
cells produce IL-12, we determined intracellular IL-12 by
FACS® analysis. Purified non-GC B cells were stimulated
by CD40L for 14–16 h before Brefeldin A was added to
the cultures for the remaining 6–8 h of culture. Cells were
harvested and analyzed for intracellular IL-12 using directly
conjugated anti–IL-12 mAb. As can be seen in Fig. 2 C,
only a small percentage (8.5%) of these B cells stained intra-
cellularly for IL-12. Preincubation with an unlabeled anti–
Figure 1. Expression of IL-12 p40
and p70 by human tonsillar B cells. (A)
t-CD40L cells induce IL-12 p40 and
p70 in B cells. Purified tonsillar B cells
(.97% CD191, 2 3 106 cells/well in
1 ml of medium) were cultured in
medium (j), on t-mock cells (r), or
on t–CD40L cells (d) for 24, 48, and
96 h when supernatants were harvested
and analyzed for the production of IL-12
by ELISA. Results are representative
for four individual experiments. Error
bars represent 1 SD from the mean. (B)
CD40L is the major signal inducing B
cells to produce IL-12. Purified tonsillar
B cells (2 3 106 cells/well in 1 ml of
medium) were stimulated with various stimuli, including anti-sIgM and anti-sIgG F(ab9)2 (a-sIg), anti-MHC class II mAbs (9-49), t-CD40L cells, IFN-g
(20 ng/ml), IL-2 (25 IU/ml), IL-4 (10 ng/ml), IL-6 (5 ng/ml), and IL-10 (10 ng/ml), for 24 h when supernatant was harvested for IL-12 analysis by
ELISA. Results represent the mean 6 SD of a total of six individual experiments.5 Schultze et al.
IL-12 mAb of the same specificity abrogated (Fig. 2 C) and
preincubation with rhIL-12 significantly decreased (data
not shown) the staining for intracellular IL-12 in these
cells, further demonstrating specific staining for IL-12. The
intensity of staining of different tonsillar samples varied
widely, whereas the percentage of positive cells was always
between 2 and 9% of total cells (total of five experiments;
Fig. 2 C, and data not shown). IL-12 production was de-
tected in both sIgD1 and sIgD2 non-GC B cells after
CD40 activation, indicating that naive and memory B cells
can be induced to produce IL-12 (Fig. 2 C). GC B cells did
not induce IL-12 p70, and this was not due to increased
cell death during culture as measured by trypan blue exclu-
sion test. Although low amounts of p40 IL-12 could be de-
tected after 96 h in some GC B cell cultures, this was not a
consistent finding. This low level of production might be
explained either by the outgrowth of few contaminating
non-GC B cells or alternatively by the differentiation of
GC B cells towards memory B cells, regaining the capabil-
ity to produce IL-12. To address this, GC B cells were dif-
ferentiated into memory B cells by CD40 activation in the
presence of IL-2 and IL-10. Cells were passaged on day 4,
and at day 7 of culture cells were restimulated via CD40
only. IL-12 was measured subsequently. Cells cultured in
this manner acquired a memory-like phenotype and re-
gained their capacity to produce IL-12, although at signifi-
cantly lower levels than in the unseparated non-GC B cell
population (data not shown).
B Cell IL-12 Production after CD40 Ligation Is Further
Enhanced by IFN-g and Blocked by IL-10. CD40 activation
of naive B cells occurs in the interfollicular areas where T
cells previously activated by DCs express the ligand for
CD40 (15). These preactivated T cells also produce cyto-
kines, including IL-2, IL-4, IL-6, IFN-g, and IL-10. IL-6
Figure 2. CD201CD382CD441 sIgD6 B
cells produce IL-12 p40 and p70. (A) Two-
color flow cytometry for CD20, CD38, and
CD44 of isolated tonsillar B cells, purified
CD201CD382CD441  sIgD6 non-GC B
cells, and CD201CD381CD442 GC B cells.
(B) IL-12 p40 and p70 are mainly induced
by non-GC B cells. B cells (d, total; r,
non-GC; j, GC) were cultured on t-CD40L
cells for 18, 24, 48, 72, or 96 h when super-
natants were harvested and analyzed for the
production for IL-12 by ELISA. Results are
representative of three individual experi-
ments. Error bars represent 1 SD from the
mean of the ELISA analysis. (C) Detection
of IL-12 in non-GC B cells by intracellular
staining. Purified tonsillar resting CD191
CD441CD382 sIgD6 non-GC B cells were
cocultured with t-CD40L cells. Brefeldin A
(10 mg/ml) was added for the last 6–8 h of
a 24-h culture. Cells were harvested and
stained for extracellular CD19 and sIgD,
and intracellular p40/p70 IL-12 and IL-6, and analyzed by FACS® analysis. Specificity controls were carried out by preincubation of the cells with satu-
rating concentrations of an unlabeled IL-12 mAb of similar specificity or by adding saturating concentrations of rhIL-12 (data not shown). Shown here is
one of five experiments. As positive control, intracellular IL-6 concentrations were analyzed, known to be induced after CD40 activation (reference 40).6 IL-12 Production by Human B Cells
production by unseparated tonsillar B cells (48) as well as
IL-12 produced by DCs (9) and macrophages (49, 50) are
negatively regulated by IL-4 and IL-10. Therefore, we
tested the effect of these T cell–derived cytokines on the
expression of CD40-induced p40 IL-12 and p70 IL-12 in
human non-GC B cells. IFN-g in combination with CD40
activation slightly increased p40 IL-12 accumulation (Fig. 3
A) but significantly increased p70 IL-12 accumulation in
these cultures. In contrast, IL-10 dramatically decreased
both IL-12 p40 and p70 (Fig. 3 A). The combination of
CD40L and IFN-g did not restore IL-12 production in the
presence of IL-10, suggesting a dominant inhibitory effect
of IL-10. Other Th2 cytokines were less inhibitory. IL-4
inhibited CD40L moderately, and IL-6 had only a minor
impact on the amount of IL-12 in the supernatant of these
B cell cultures (data not shown). In contrast to IL-10, the
inhibitory effect of IL-4 could be partially reversed by
IFN-g. IL-2 showed no significant effects and could restore
neither IL-4– nor IL-10–mediated inhibition (data not
shown). In control experiments and confirming the find-
ings of others (39), we detected very high levels of IL-6 in
cultures of non-GC B cells (Fig. 3 B) but not GC B cells
(data not shown) stimulated with CD40L. The addition of
IL-4 dramatically increased IL-6 production, addition of
IL-2 and IFN-g had no influence, but IL-10 significantly
decreased IL-6 production by the CD40-activated B cells
(Fig. 3 B). However, in the presence of IL-4, IL-10 did not
reduce IL-6 production, suggesting again a hierarchy of
signals with IL-4 dominant over IL-10, IL-2, and IFN-g.
Taken together, these data suggest that CD40 activation of
B cells is the major stimulus of IL-12 and IL-6. However,
the two cytokines are differentially regulated by T cell cy-
tokines: IL-2 and IFN-g increase IL-12 production and IL-4
increases IL-6 production. In contrast, IL-10 can suppress
IL-12 and IL-6 production in the absence of IL-4.
B Cell–derived IL-12 Is Bioactive. To determine whether
the p70 IL-12 heterodimer detected in supernatants of
CD40-activated tonsillar B cells is bioactive, we measured
the influence of B cell culture–derived supernatants on the
IFN-g production of activated CD31CD41 T cells. In
control cultures, T cells were stimulated with PMA and
anti-CD28 mAbs in the presence of increasing concentra-
tions of exogenous rhIL-12. IFN-g could be detected at
low levels in cultures without exogenous IL-12, but in-
creased significantly from 22 to 480 ng/ml IFN-g when
between 1 and 1,000 pg/ml of exogenous IL-12 was
added. The addition of supernatants from B cell cultures
(24-h cultures) at 50% vol induced IFN–g production by
the T cells equivalent to the effect of 48–114 pg/ml rIL-12
(Fig. 4). This suggests that z50–250 pg/ml of bioactive IL-
12 is present in B cell culture supernatants after 24 h, con-
firming our ELISA results. The addition of neutralizing
anti–IL-12 mAb (10 mg/ml) to T cells stimulated in the
Figure 3. Regulation of IL-12 and IL-6 production by T cell cytokines. Non-GC B cells were cultured on t-CD40L cells in the presence of IFN-g
(20 ng/ml), IL-4 (10 ng/ml), IL-10 (5 ng/ml), or their combinations. Supernatants were harvested after 24, 48, or 96 h and analyzed for IL-12 by ELISA.
(A) IL-12 production. (B) IL-6 production. One representative experiment of three experiments performed is shown here.
Figure 4. B cell–derived IL-12 induces T cells to produce IFN-g.
CD31CD41CD45RA1 enriched T cells (98% CD31 CD41  .  75%
CD45RA) were stimulated with PMA (1 ng/ml) plus CD28 mAbs (2
mg/ml) with or without rhIL-12 p70 at concentrations ranging from 1 to
1,000 pg or with supernatants (a 50% vol of 200 ml final vol) from tonsil-
lar B cells cultured for 24 h on t-CD40L cells. Where indicated, neutral-
izing anti–IL-12 mAb (a–IL-12) was added. After 3 d, supernatants were
harvested and analyzed for IFN-g production by ELISA.7 Schultze et al.
presence of B cell culture supernatants reduced IFN-g pro-
duction by .80%, further supporting that these superna-
tants contained bioactive IL-12. To further confirm that
IL-12 was derived from CD40-activated B cells, we cocul-
tured allogeneic CD41 T cells with previously CD40-acti-
vated non-GC B cells and rechallenged the T cells with the
same target cells to analyze the cytokine pattern in these
cultures (Table I). Similar to experiments described previ-
ously using DCs (9, 10), T cell–derived IFN-g production
is mainly dependent on the production of IL-12 by CD40-
activated non-GC B cells. Blockade of IL-12 during chal-
lenge reduced IFN-g production during rechallenge by
z85%, whereas T cell proliferation in the presence of anti–
IL-12 mAbs decreased only #25%. IL-4 and IL-10 were
not detected in any culture supernatant (Table I).
Resting B Cells Maintain the Cytokine Profile of Previously
Activated T Cells. Recent in vivo analysis demonstrated
that T cells primarily activated by DCs migrate towards the
B cell zone to interact with antigen-specific naive and/or
memory B cells and that CD40L–CD40 interactions occur
during this phase of the immune response (29). To study
this interaction with regard to our observation that CD40
and IFN-g stimulation induces these B cells to produce IL-
12, the following experiment was performed. Naive cord
blood T cells were primarily stimulated with anti-CD3 and
anti-CD28 mAbs bound to tossyl beads representing artifi-
cial APCs in the presence of IL-12 and anti–IL-4 mAbs to
skew towards a Th1 phenotype, or with IL-4 and anti–
IFN-g mAbs to skew towards a Th2 phenotype. Cells
were restimulated after 3–6 d with freshly isolated irradi-
ated allogeneic resting CD191CD381 sIgD6 tonsillar B
cells, and cytokines were measured 48 h later. As shown in
Fig. 5 A, T cells skewed towards a Th1 phenotype pro-
duced significant amounts of IFN-g in response to incuba-
tion with resting allogeneic B cells as well as when restimu-
lated with CD3 and CD28 mAb beads. In contrast, Th2
cells could not be induced to produce IFN-g. However,
Th2 cells were induced to produce small amounts of IL-4
in the presence of the B cells. IL-4 was also barely detect-
able in cultures primarily skewed towards Th1 cells during
Table I. Cytokine Production and Proliferation during Rechallenge with CD40-activated Irradiated Non-GC B Cells
Primary activation Rechallenge IFN-g IL-4 IL-6 IL-10 Proliferation
ng/ml pg/ml pg/ml pg/ml cpm
Experiment 1
CD40-B CD40-B 14,791 6 2,350 ,40 71.5 6 16.3 ,40 297,101 6 62,519
CD40-B 1 a–IL-12 CD40-B 2,272 6 575 ,40 139.0 6 38.2 ,40 221,185 6 17,542
Experiment 2
CD40-B CD40-B 10,006 6 1,077 ,40 41.0 6 19.8 ,40 225,844 6 26,765
CD40-B 1 a–IL-12 CD40-B 1,321 6 39 ,40 124.0 6 33.9 ,40 219,761 6 7,865
Preferential production of IFN-g by T cells stimulated with CD40-activated non-GC B cells is mainly due to B cells’ IL-12 production.
CD31CD41 T cells enriched for the CD41CD45RA1 subpopulation (.75% CD45RA) were primarily activated with CD40-activated irradiated
non-GC B cells (72-h preactivation of the B cells) with or without anti–IL-12 mAbs (10 mg/ml) for 5 d, rested for 48 h in medium alone, and re-
challenged with the same irradiated B cells. Supernatants of these cultures were harvested after 24, 48 (shown here), 72, or 96 h and analyzed by
ELISA for IFN-g, IL-4, IL-6, or IL-10 (detection level of all ELISA was 40 pg/ml). T cell proliferation was measured by [3H]Tdr incorporation for
the last 18 h of a 72-h culture period. Shown here are mean 6 SD of triplicates. CD40-B, CD40-activated irradiated non-GC B cells.
Figure 5. Resting B cells sustain the cytokine profile of previously activated T cells. (A) To mimic the interaction of DCs and naive T cells, cord blood
CD31CD41CD45RA1 T cells were primed with CD3 and CD28 mAbs bound to magnetic beads in the presence of IL-2 and either IL-12 or IL-4 to
skew towards a Th1 or Th2 phenotype. Cells were rested and restimulated with allogeneic tonsillar resting B cells (1:1 ratio) or CD3 plus CD28 mAb
beads as a positive control. Supernatants of these cultures were harvested 48 h later and analyzed for IFN-g or IL-4 by ELISA. (B) To determine the role
of CD40L–CD40 interaction and IL-12 for the induction of IFN-g in Th1 cells, CD40L and/or IL-12 were blocked during T–B cell cultures. IFN-g
production in these cultures was assessed as described.8 IL-12 Production by Human B Cells
restimulation with CD3 and CD28 mAb beads, but not
when restimulated with resting allogeneic B cells. Staining
for intracellular IFN-g and IL-4 showed that the CD31 T
cells were the source of these cytokines in these cultures
(data not shown). To further support the role of CD40L–
CD40 interaction and IL-12 production by B cells for the
sustained Th1 phenotype, the same experiments were per-
formed in the presence of neutralizing anti–IL-12 mAb
and/or blocking anti-CD40L mAb during T–B cultures
(Fig. 5 B). Blockade of IL-12 or CD40L significantly re-
duced IFN-g production, whereas blocking both almost
totally abrogated IFN-g in the supernatant of these cul-
tures.
Discussion
IL-12 was originally identified in and cloned from hu-
man EBV-transformed B cell lines (35–38), and indirect
evidence exists that this cytokine is expressed in normal pe-
ripheral blood–derived human B cells (49, 51). However,
the major stimuli for the induction of IL-12 by normal hu-
man B cells in secondary lymphoid organs and its regula-
tion have been unclear. Moreover, recent data from mu-
rine models suggest that IL-12 is not expressed in murine B
cells (52, 53). CD40 ligation, a major signal for the induc-
tion of IL-12 in APCs, does not lead to IL-12 by murine B
cells (52, 53). In contrast to the findings in murine B cells,
we demonstrate that human tonsillar non-GC B cells are
induced to produce IL-12 after CD40 activation, but not
by B cell receptor cross-linking. The Th1 cytokine IFN-g
is synergistic with CD40, whereas Th2 cytokines IL-4 and
IL-10, but not IL-6, are inhibitory for IL-12 production by
B cells. IL-12 produced by these human B cells is bioactive
and induces IFN-g production by allogeneic CD31CD41
T cells. IL-6 has been recently suggested as the cytokine
expressed by APCs leading to Th2 skewing (18). Tonsillar
non-GC B cells expressed IL-6 after CD40 activation, and
expression was markedly increased in the presence of IL-4.
In contrast to IL-12, IL-6 was not suppressed by IL-10 in
the presence of IL-4. These data suggest an additional level
of feedback stimulation and inhibition that occur during
cognate T–B interactions (1, 34).
Although human peripheral blood B cells have been sug-
gested to contribute to the IL-12 production of human
PBMCs (51) induced by Staphylococcus aureus Cowan I
(SAC), it has been recently reported that murine B cells
from BALB/c mice fail to produce IL-12 in response to
SAC and other stimuli (52). In this context, it will be of in-
terest whether a general difference between human and
murine B cells exists, or whether this is a specific phenom-
enon of BALB/c mice. This is of particular interest, since
this syngeneic strain has been shown neither to develop nor
to maintain Th1 responses to Leishmania major (54). This is
despite the fact that DCs of BALB/c mice do not differ in
their capacity to produce IL-12 from C57BL/6 mice (13),
known to develop Th1 responses to L. major (55). Al-
though the defect in mounting a Th1 response in BALB/c
mice is believed to result from a defect in the T cell com-
partment, it is not well characterized whether additional
defects in the B cell compartment exist (56). C57BL/6 and
C3H mice usually demonstrate Th1 responses to L. major
that can be redirected towards Th2 in the presence of anti–
IL-12 mAbs (57). However, after termination of treatment
with anti–IL-12 mAbs, the immune response switches back
to a Th1 response, which is maintained thereafter (57). It is
tempting to speculate whether B cells from these mice
might differ from BALB/c mice in their capacity to pro-
duce IL-12. Studies using CD402/2 mice have also unrav-
eled that the induction of IL-12 after CD40 activation is
necessary for the generation and maintenance of Th1 re-
sponses (7–10). However, it has not been studied directly
whether IL-12 production is restricted to APCs, or if adop-
tively transferred CD401 B cells could overcome the lack
of Th1 responses in CD402/2 mice.
The amount of IL-12 produced by human DCs after
CD40 activation is severalfold higher than we could dem-
onstrate for human B cells. Cella and colleagues reported
p40 IL-12 production by DCs in excess of 100 ng/ml and
p70 IL-12 production higher than 10 ng/ml (10). In this
context, it is clear that human B cells produce lower
amounts of IL-12 than DCs and are not the major source
of IL-12. Our own experiments (data not shown) using
monocyte-derived DCs support these earlier findings, al-
though we could not detect equally high levels as reported
(10). When and why do B cells produce IL-12? Since
CD40L and IFN-g were the major stimuli for human non-
GC B cells to produce IL-12, it is most likely that previ-
ously activated T cells expressing CD40L and IFN-g in-
duce naive or memory B cells to express IL-12 during their
first contact (21, 29). The production of IL-12 by B cells
after cognate interaction with T cells could serve as a posi-
tive feedback mechanism during the expansion of Th1
cells, ensuring the polarization of these T cells and other T
cells recruited to the site (Fig. 6). Our data suggest that the
Figure 6. B cells maintain a Th1 phenotype by a positive feedback
mechanism via CD40 and IL-12. Resting naive and memory B cells pro-
duce IL-12 when encountering activated Th1 cells expressing CD40L
and IFN-g, sustaining the Th1 phenotype. In contrast, when resting B
cells encounter Th2 cells producing IL-4, they do not induce IFN-g pro-
duction but rather maintain the T cells’ IL-4 production.9 Schultze et al.
simultaneous production of CD40-induced IL-6, a cyto-
kine indicated as an APC-derived factor inducing Th2 dif-
ferentiation (18), does not seem to influence this feedback
pathway. In contrast, the Th2 cytokines IL-4 and IL-10 are
potent inhibitors of B cell–derived IL-12. From these data
we conclude that the inhibition of IL-12 production after
CD40 activation is similarly regulated by human macro-
phages, DCs (58), and B cells. Similar to IL-12, IL-6 pro-
duction induced by CD40 ligation in human B cells was
further regulated by T cell cytokines. The Th2 cytokine
IL-4 dramatically increased IL-6 production by these B
cells and IL-10 did not inhibit this effect, suggesting a posi-
tive feedback mechanism by Th2-polarized cells. Of note,
when IL-4 was absent, IL-10 reduced CD40-mediated IL-6
production, suggesting that the effect of IL-10 on produc-
tion of IL-6 by B cells depends on the cytokine milieu
present.
Indeed, CD40L is expressed in vivo in the outer T cell
zone (59) and the B cell area (29), areas where CD40L1 T
cells are juxtaposed to antigen-specific B cells. Our data
strongly indicate that the production of IL-12 and IL-6 is a
consequence of the interaction of resting B cells with al-
ready activated T cells. Indeed, during T–B contact,
CD40L–CD40 interaction appears to be the most impor-
tant signal for IL-12 and IL-6 production, and this is fur-
ther regulated by T cell–derived cytokines. Since B cells
did not produce IL-12 or significant amounts of IL-6 (data
not shown) to sIg cross-linking, it seems unlikely that B
cells primarily activated by antigen are responsible for
skewing T cell differentiation. Therefore, we add to the
model initially presented by Janeway and colleagues (1) and
introduce the production of these cytokines by B cells in a
positive feedback mechanism. B cells may play an impor-
tant role for amplification and maintenance of an immune
response primarily initiated by DCs or macrophages (Fig.
6). When T cells are primarily activated by DCs in the in-
terfollicular area, they migrate 24–48 h later to the outer T
cell zone (21) and subsequently to the B cell area (29)
where they meet antigen-specific B cells. It is this interac-
tion that leads to massive expansion of both T and B cells
(60, 61). When B cells meet IFN-g–producing T cells ex-
pressing surface CD40L, they produce IL-12, further rein-
forcing IFN-g production by the adjacent T cells (Fig. 6).
In contrast, T cells that express CD40L in the context of
IL-4 and IL-10 suppress IL-12 production but further sup-
port IL-4 production by these T cells. Naive T cells could
be primed in the presence of exogenous IL-4 and then re-
stimulated with resting B cells to produce low levels of
IL-4. Blocking of CD40L completely abrogated IL-4 in
these cultures, whereas addition of anti–IL-6 mAb slightly
decreased IL-4 production (data not shown), suggesting
that although IL-6 plays a role in regulating T cell re-
sponses, other factors are also likely to be important.
Finally, our results are relevant for immunotherapeutic
strategies. We have previously described a simple method
to generate large numbers of B cells from human peripheral
blood by stimulation with CD40L and IL-4. These cells are
highly efficient APCs and can present antigen to both
CD41 and CD81 T cells. Preliminary results suggest that
these B cells produce IL-12 (Schultze, J.L., unpublished re-
sults), and this is the most likely explanation for the induc-
tion of the very high amounts of IFN-g by the T cells
stimulated with CD40-activated B cells (16). Therefore,
this makes these B cells a very attractive alternative to DCs
for ex vivo or in vivo T cell–mediated immunotherapy.
We thank Glenn Dranoff, David Sherr, Robert Vonderheide, and David Frank for critically reading the
manuscript. 
J.L. Schultze was a Fellow of the Lymphoma Research Foundation of America when most of the work was
performed and is currently a Special Fellow of the Leukemia Society of America. This work was supported
by National Institutes of Health grant CA66996 to L.M. Nadler.
Address correspondence to Joachim L. Schultze, Department of Adult Oncology, Dana-Farber Cancer
Institute, 44 Binney St., D542, Boston, MA 02115. Phone: 617-632-2201; Fax: 617-734-8146; E-mail:
schultze@mbcrr.harvard.edu
Received for publication 24 March 1998 and in revised form 27 October 1998.
References
1. Mamula, M.J., and C.A. Janeway, Jr. 1993. Do B cells drive
the diversification of immune responses? Immunol. Today. 14:
151–152.
2. Romagnani, S. 1997. The Th1/Th2 paradigm. Immunol. To-
day. 18:263–266.
3. Mosmann, T.R., and S. Sad. 1996. The expanding universe
of T-cell subsets: Th1, Th2 and more. Immunol. Today. 17:
138–146.
4. Constant, S.L., and K. Bottomly. 1997. Induction of Th1
and Th2 CD41 T cell responses: the alternative approaches.
Annu. Rev. Immunol. 15:297–322.
5. Abbas, A.K., K.M. Murphy, and A. Sher. 1996. Functional
diversity of helper T lymphocytes. Nature. 383:787–793.
6. Carter, L.L., and R.W. Dutton. 1996. Type 1 and type 2: a
fundamental dichotomy for all T-cell subsets. Curr. Opin. Im-
munol. 8:336–342.
7. Macatonia, S.E., N.A. Hosken, M. Litton, P. Vieira, C.S.
Hsieh, J.A. Culpepper, M. Wysocka, G. Trinchieri, K.M.10 IL-12 Production by Human B Cells
Murphy, and A. O’Garra. 1995. Dendritic cells produce IL-
12 and direct the development of Th1 cells from naive
CD41 T cells. J. Immunol. 154:5071–5079.
8. Heufler, C., F. Koch, U. Stanzl, G. Topar, M. Wysocka, G.
Trinchieri, A. Enk, R.M. Steinman, N. Romani, and G.
Schuler. 1996. Interleukin-12 is produced by dendritic cells
and mediates T helper 1 development as well as interferon-
gamma production by T helper 1 cells. Eur. J. Immunol. 26:
659–668.
9. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E.
Kampgen, N. Romani, and G. Schuler. 1996. High level IL-
12 production by murine dendritic cells: upregulation via
MHC class II and CD40 molecules and downregulation by
IL-4 and IL-10. J. Exp. Med. 184:741–746.
10. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A.
Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on den-
dritic cells triggers production of high levels of interleukin-12
and enhances T cell stimulatory capacity: T–T help via APC
activation. J. Exp. Med. 184:747–752.
11. Skeen, M.J., M.A. Miller, T.M. Shinnick, and H.K. Ziegler.
1996. Regulation of murine macrophage IL-12 production.
Activation of macrophages in vivo, restimulation in vitro,
and modulation by other cytokines. J. Immunol. 156:1196–
1206.
12. Reiner, S.L., S. Zheng, Z.E. Wang, L. Stowring, and R.M.
Locksley. 1994. Leishmania promastigotes evade interleukin
12 (IL-12) induction by macrophages and stimulate a broad
range of cytokines from CD41 T cells during initiation of in-
fection. J. Exp. Med. 179:447–456.
13. Sousa, C.R., S. Hieny, T. Scharton-Kersten, D. Jankovic, H.
Charest, R.N. Germain, and A. Sher. 1997. In vivo micro-
bial stimulation induces rapid CD40 ligand–independent
production of interleukin 12 by dendritic cells and their re-
distribution to T cell areas. J. Exp. Med. 186:1819–1829.
14. Johnson, L.L., and P.C. Sayles. 1997. Interleukin-12, den-
dritic cells, and the initiation of host-protective mechanisms
against Toxoplasma gondii. J. Exp. Med. 186:1799–1802.
15. Banchereau, J., F. Bazan, D. Blanchard, F. Briere, J.P. Gal-
izzi, C. Vankooten, Y.J. Liu, F. Rousset, and S. Saeland.
1994. The CD40 antigen and its ligand. Annu. Rev. Immunol.
12:881–922.
16. Schultze, J.L., S. Michalak, M.J. Seamon, G. Dranoff, K.
Jung, J. Daley, J.C. Delgado, J.G. Gribben, and L.M. Nadler.
1997. CD40-activated human B cells: an alternative source of
highly efficient antigen presenting cells to generate autolo-
gous antigen-specific T cells for adoptive immunotherapy. J.
Clin. Invest. 100:2757–2765.
17. Pistoia, V. 1997. Production of cytokines by human B cells in
health and disease. Immunol. Today. 18:343–350.
18. Rincon, M., J. Anguita, T. Nakamura, E. Fikrig, and R.A.
Flavell. 1997. Interleukin (IL)-6 directs the differentiation of
IL-4–producing CD41 T cells. J. Exp. Med. 185:461–469.
19. Van Snick, J. 1990. Interleukin-6: an overview. Annu. Rev.
Immunol. 8:253–278.
20. Ingulli, E., A. Mondino, A. Khoruts, and M.K. Jenkins.
1997. In vivo detection of dendritic cell antigen presentation
to CD41 T cells. J. Exp. Med. 185:2133–2141.
21. MacLennan, I.C., A. Gulbranson-Judge, K.M. Toellner, M.
Casamayor-Palleja, E. Chan, D.M. Sze, S.A. Luther, and
H.A. Orbea. 1997. The changing preference of T and B cells
for partners as T-dependent antibody responses develop. Im-
munol. Rev. 156:53–66.
22. Flamand, V., T. Sornasse, K. Thielemans, C. Demanet, O.
Leo, and J.M. Urbain, and M. Moser. 1993. Vaccination
with tumor-antigen-pulsed dendritic cells induces in vivo re-
sistance to a B cell lymphoma. Adv. Exp. Med. Biol. 329:611–
616.
23. Flamand, V., T. Sornasse, K. Thielemans, C. Demanet, M.
Bakkus, H. Bazin, F. Tielemans, O. Leo, J. Urbain, and M.
Moser. 1994. Murine dendritic cells pulsed in vitro with tu-
mor antigen induce tumor resistance in vivo. Eur. J. Immunol.
24:605–610.
24. Grabbe, S., S. Beissert, T. Schwarz, and R.D. Granstein.
1995. Dendritic cells as initiators of tumor immune re-
sponses: a possible strategy for tumor immunotherapy? Immu-
nol. Today. 16:117–121.
25. Gabrilovich, D.I., H.T. Cunningham, and D.P. Carbone.
1996. IL-12 and mutant p53 peptide-pulsed dendritic cells
for the specific immunotherapy of cancer. J. Immunother. 19:
414–418.
26. Paglia, P., C. Chiodoni, M. Rodolfo, and M.P. Colombo.
1996. Murine dendritic cells loaded in vitro with soluble pro-
tein prime cytotoxic T lymphocytes against tumor antigen in
vivo. J. Exp. Med. 183:317–322.
27. Celluzzi, C.M., J.I. Mayordomo, W.J. Storkus, M.T. Lotze,
and L.D. Falo, Jr. 1996. Peptide-pulsed dendritic cells induce
antigen-specific CTL-mediated protective tumor immunity.
J. Exp. Med. 183:283–287.
28. Zitvogel, L., J.I. Mayordomo, T. Tjandrawan, A.B. DeLeo,
M.R. Clarke, M.T. Lotze, and W.J. Storkus. 1996. Therapy
of murine tumors with tumor peptide–pulsed dendritic cells:
dependence on T cells, B7 costimulation, and T helper cell
1–associated cytokines. J. Exp. Med. 183:87–97.
29. Garside, P., E. Ingulli, R.R. Merica, J.G. Johnson, R.J. No-
elle, and M.K. Jenkins. 1998. Visualization of specific B and
T lymphocyte interactions in the lymph node. Science. 281:
96–99.
30. Zheng, W., and R.A. Flavell. 1997. The transcription factor
GATA-3 is necessary and sufficient for Th2 cytokine gene
expression in CD4 T cells. Cell. 89:587–596.
31. Nakamura, T., Y. Kamogawa, K. Bottomly, and R.A. Fla-
vell. 1997. Polarization of IL-4- and IFN-g-producing
CD41 T cells following activation of naive CD41 T cells. J.
Immunol. 158:1085–1094.
32. Sornasse, T., P.V. Larenas, K.A. Davis, J.E. de Vries, and H.
Yssel. 1996. Differentiation and stability of T helper 1 and 2
cells derived from naive human neonatal CD41 T cells, ana-
lyzed at the single-cell level. J. Exp. Med. 184:473–483.
33. Murphy, E., K. Shibuya, N. Hosken, P. Openshaw, V.
Maino, K. Davis, K. Murphy, and A. O’Garra. 1996. Re-
versibility of T helper 1 and 2 populations is lost after long-
term stimulation. J. Exp. Med. 183:901–913.
34. Clark, E.A., and J.A. Ledbetter. 1994. How B and T cells talk
to each other. Nature. 367:425–428.
35. Kobayashi, M., L. Fitz, M. Ryan, R.M. Hewick, S.C. Clark,
S. Chan, R. Loudon, F. Sherman, B. Perussia, and G.
Trinchieri. 1989. Identification and purification of natural
killer cell stimulatory factor (NKSF), a cytokine with multi-
ple biologic effects on human lymphocytes. J. Exp. Med. 170:
827–845.
36. Stern, A.S., F.J. Podlaski, J.D. Hulmes, Y.C. Pan, P.M.
Quinn, A.G. Wolitzky, P.C. Familletti, D.L. Stremlo, T.
Truitt, R. Chizzonite, et al. 1990. Purification to homogene-
ity and partial characterization of cytotoxic lymphocyte mat-
uration factor from human B-lymphoblastoid cells. Proc. Natl.
Acad. Sci. USA. 87:6808–6812.11 Schultze et al.
37. Gubler, U., A.O. Chua, D.S. Schoenhaut, C.M. Dwyer, W.
McComas, R. Motyka, N. Nabavi, A.G. Wolitzky, P.M.
Quinn, P.C. Familletti, et al. 1991. Coexpression of two dis-
tinct genes is required to generate secreted bioactive cyto-
toxic lymphocyte maturation factor. Proc. Natl. Acad. Sci.
USA. 88:4143–4147.
38. Wolf, S.F., P.A. Temple, M. Kobayashi, D. Young, M.
Dicig, L. Lowe, R. Dzialo, L. Fitz, C. Ferenz, R.M.
Hewick, et al. 1991. Cloning of cDNA for natural killer cell
stimulatory factor, a heterodimeric cytokine with multiple
biologic effects on T and natural killer cells. J. Immunol. 146:
3074–3081.
39. Burdin, N., L. Galibert, P. Garrone, I. Durand, J. Ban-
chereau, and F. Rousset. 1996. Inability to produce IL-6 is a
functional feature of human germinal center B lymphocytes.
J. Immunol. 156:4107–4113.
40. Clark, E.A., and G.L. Shu. 1990. Association between IL-6
and CD40 signaling. IL-6 induces phosphorylation of CD40
receptors. J. Immunol. 145:1400–1406.
41. Vremec, D., M. Zorbas, R. Scollay, D.J. Saunders, C.F. Ar-
davin, L. Wu, and K. Shortman. 1992. The surface pheno-
type of dendritic cells purified from mouse thymus and
spleen: investigation of the CD8 expression by a subpopula-
tion of dendritic cells. J. Exp. Med. 176:47–58.
42. Smith, J.L., and C.R. Barker. 1973. T and B cell separation
by sheep-red-cell rosetting. Lancet. 1:558–559.
43. Schultze, J.L., A.A. Cardoso, G.J. Freeman, M.J. Seamon, J.
Daley, G.S. Pinkus, J.G. Gribben, and L.M. Nadler. 1995.
Follicular lymphomas can be induced to present alloantigen
efficiently: a conceptual model to improve their tumor im-
munogenicity. Proc. Natl. Acad. Sci. USA. 92:8200–8204.
44. Schultze, J.L., M.J. Seamon, S. Michalak, J.G. Gribben, and
L.M. Nadler. 1997. Autologous tumor infiltrating T cells cy-
totoxic for follicular lymphoma cells can be expanded in
vitro.  Blood. 89:3806–3816.
45. Bleul, C.C., J.L. Schultze, and T.A. Springer. 1998. B lym-
phocyte chemotaxis regulated in association with microana-
tomic localization, differentiation state, and B cell receptor
engagement. J. Exp. Med. 187:753–762.
46. Astier, A., H. Avraham, S.N. Manie, J. Groopman, T. Canty,
S. Avraham, and A.S. Freedman. 1997. The related adhesion
focal tyrosine kinase is tyrosine-phosphorylated after beta1-
integrin stimulation in B cells and binds to p130cas. J. Biol.
Chem. 272:228–232.
47. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cy-
tokine with immunoregulatory functions that bridge innate
resistance and antigen-specific adaptive immunity. Annu.
Rev. Immunol. 13:251–276.
48. Burdin, N., C. van Kooten, L. Galibert, J.S. Abrams, J.
Wijdenes, J. Banchereau, and F. Rousset. 1995. Endogenous
IL-6 and IL-10 contribute to the differentiation of CD40-
activated human B lymphocytes. J. Immunol. 154:2533–2544.
49. D’Andrea, A., M. Aste-Amezaga, N.M. Valiante, X. Ma, M.
Kubin, and G. Trinchieri. 1993. Interleukin 10 (IL-10) in-
hibits human lymphocyte interferon g production by sup-
pressing natural killer cell stimulatory factor/IL-12 synthesis
in accessory cells. J. Exp. Med. 178:1041–1048.
50. D’Andrea, A., X. Ma, M. Aste-Amezaga, C. Paganin, and G.
Trinchieri. 1995. Stimulatory and inhibitory effects of inter-
leukin (IL)-4 and IL-13 on the production of cytokines by
human peripheral blood mononuclear cells: priming for IL-
12 and tumor necrosis factor a production. J. Exp. Med. 181:
537–546.
51. D’Andrea, A., M. Rengaraju, N.M. Valiante, J. Chehimi, M.
Kubin, M. Aste, S.H. Chan, M. Kobayashi, D. Young, E.
Nickbarg, et al. 1992. Production of natural killer cell stimu-
latory factor (interleukin 12) by peripheral blood mononu-
clear cells. J. Exp. Med. 176:1387–1398.
52. Guery, J.C., F. Ria, F. Galbiati, and L. Adorini. 1997. Nor-
mal B cells fail to secrete interleukin-12. Eur. J. Immunol. 27:
1632–1639.
53. Maruo, S., M. Oh-hora, H.J. Ahn, S. Ono, M. Wysocka, Y.
Kaneko, H. Yagita, K. Okumura, H. Kikutani, T. Kishim-
oto, et al. 1997. B cells regulate CD40 ligand-induced IL-12
production in antigen-presenting cells (APC) during T cell/
APC interactions. J. Immunol. 158:120–126.
54. Reiner, S.L., and R.M. Locksley. 1995. The regulation of
immunity to Leishmania major. Annu. Rev. Immunol. 13:151–
177.
55. Guler, M.L., J.D. Gorham, C.S. Hsieh, A.J. Mackey, R.G.
Steen, W.F. Dietrich, and K.M. Murphy. 1996. Genetic sus-
ceptibility to Leishmania: IL-12 responsiveness in TH1 cell
development. Science. 271:984–987.
56. Gorham, J.D., M.L. Guler, R.G. Steen, A.J. Mackey, M.J.
Daly, K. Frederick, W.F. Dietrich, and K.M. Murphy. 1996.
Genetic mapping of a murine locus controlling development
of T helper 1/T helper 2 type responses. Proc. Natl. Acad. Sci.
USA. 93:12467–12472.
57. Hondowicz, B.D., T.M. Scharton-Kersten, D.E. Jones, and
P. Scott. 1997. Leishmania major-infected C3H mice treated
with anti-IL-12 mAb develop but do not maintain a Th2 re-
sponse. J. Immunol. 159:5024–5031.
58. Takenaka, H., S. Maruo, N. Yamamoto, M. Wysocka, S.
Ono, M. Kobayashi, H. Yagita, K. Okumura, T. Hamaoka,
G. Trinchieri, and H. Fujiwara. 1997. Regulation of T cell-
dependent and -independent IL-12 production by the three
Th2-type cytokines IL-10, IL-6, and IL-4. J. Leukocyte Biol.
61:80–87.
59. Van den Eertwegh, A.J., R.J. Noelle, M. Roy, D.M. Shep-
herd, A. Aruffo, J.A. Ledbetter, W.J. Boersma, and E. Claas-
sen. 1993. In vivo CD40–gp39 interactions are essential for
thymus-dependent humoral immunity. I. In vivo expression
of CD40 ligand, cytokines, and antibody production delin-
eates sites of cognate T–B cell interactions. J. Exp. Med. 178:
1555–1565.
60. Gulbranson-Judge, A., and I. MacLennan. 1996. Sequential
antigen-specific growth of T cells in the T zones and follicles
in response to pigeon cytochrome c. Eur. J. Immunol. 26:
1830–1837.
61. Liu, Y.J., J. Zhang, P.J. Lane, E.Y. Chan, and I.C. MacLen-
nan. 1991. Sites of specific B cell activation in primary and
secondary responses to T cell-dependent and T cell-indepen-
dent antigens. Eur. J. Immunol. 21:2951–2962.12 IL-12 Production by Human B Cells